FDA Puts Sleep Aid Dreams on Hold with Hearing Denial
Published Date: 3/7/2025
Notice
Summary
The FDA said no to Vanda Pharmaceuticals’ request for a hearing about their new drug application for HETLIOZ capsules, which are meant to help people who have trouble falling asleep. This means the FDA won’t approve the new use of HETLIOZ right now. Patients and doctors waiting for this treatment update will have to keep waiting, and Vanda won’t get the green light or any new sales from this application yet.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
FDA Refuses HETLIOZ Supplemental Approval
The FDA refused to approve Vanda Pharmaceuticals’ supplemental new drug application (sNDA 205677-012) for HETLIOZ (tasimelteon) 20 mg to treat insomnia with difficulty falling asleep. Because the FDA also denied Vanda’s request for a hearing, doctors and patients waiting for this new use must keep waiting and Vanda cannot market or sell HETLIOZ for that use now.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-03696, U.S. Integrated Ocean Observing System (IOOS®) Advisory Committee Public Meeting Cancelled
Heads up! The U.S. Integrated Ocean Observing System (IOOS) Advisory Committee’s public meeting planned for March 12-14, 2025, has been canceled. This affects anyone looking forward to updates or input during those dates, but no money or new deadlines are involved. Stay tuned for future meeting plans and updates!
Next: 2025-03699, Arbitrator's Personal Data Questionnaire
The FMCS is asking for feedback on a form called the Arbitrator's Personal Data Questionnaire, which helps them keep a list of qualified arbitrators. These arbitrators are private citizens who get paid by the parties they help, not by FMCS. This update ensures only the best folks make the list, keeping arbitration fair and smooth—no extra costs or delays expected.